Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + saffron is a combination of two botanical extracts—curcumin (the primary active compound in turmeric, Curcuma longa) and saffron (derived from the stigmas of Crocus sativus). This combination has been studied primarily as a dietary supplement for its potential antidepressant and anxiolytic effects. Clinical trials have shown that combined administration of low-dose curcumin (250 mg twice daily) with saffron (15 mg twice daily) over 12 weeks can significantly reduce symptoms of major depressive disorder and anxiety compared to placebo[1][3][6][7]. The mechanism is thought to involve multiple pathways: - Curcumin exhibits anti-inflammatory, antioxidant, and neuroprotective properties; it may modulate neurotransmitter levels such as serotonin and dopamine. - Saffron appears to boost serotonin production, lower cortisol levels, preserve gamma-aminobutyric acid (GABA), and also acts as an antioxidant[6]. The synergy between these botanicals may provide broader mood-regulating effects than either alone. Both are generally well-tolerated at studied doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + saffron.